1

Single-cell genetics identifies cell type-specific causal mechanisms in complex traits and diseases

Albert Henry[1,2,3,4,*], Anne Senabouth[1,2,*], Rika Tyebally[1,2], Blake Bowen[1,2,3], Peter C. Allen[1,2], Eleanor Spenceley[1,2,3], Eszter Sagi-Zsigmond[1], Anna S.E. Cuomo[1,2,3,5,6], Jianan Fan[1,2], Hao Lawrence Huang[1,2,3], Hope A. Tanudisastro[2,5,6,7], Angli Xue[1,2,3], Katrina M. de Lange[1,2,3], Gemma A. Figtree[8,9], Alex W. Hewitt[10,11,12], Daniel G. MacArthur[2,5,6], Joseph E. Powell[1,2,3,**]

[1] Translational Genomics Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
[2] Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia
[3] UNSW Cellular Genomics Futures Institute, University of New South Wales, Sydney, NSW, Australia
[4] Institute of Cardiovascular Science, University College London, London, UK
[5] Centre for Population Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia
[6] Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia
[7] Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
[8] Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
[9] Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia
[10] Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
[11] Department of Ophthalmology, Royal Hobart Hospital, Hobart, TAS, Australia
[12] Centre for Eye Research Australia, University of Melbourne, East Melbourne, VIC, Australia

* Equal contribution
** Correspondence: j.powell@garvan.org.au

Abstract

Genome-wide association studies (GWAS) have been instrumental in uncovering the genetic basis of complex traits. When integrated with expression quantitative trait loci (eQTL) mapping, they can elucidate how risk loci influence traits through gene regulatory mechanisms. Recent single-cell eQTL (sc-eQTL) studies suggest that genetic effects on gene expression are often cell type- and subtype-specific, but such datasets have so far been underpowered for causal inference. Here, we leverage results from sc-eQTL mapping in the TenK10K project, comprising 154,932 common variant sc-eQTL across 28 immune cell types derived from matched whole-genome sequencing (WGS) and single-cell RNA-sequencing (scRNA-seq) of over 5 million peripheral blood mononuclear cells (PBMCs) from 1,925 individuals. We present a catalogue of cell type-specific causal effects of gene expression on 53 diseases (spanning 58,058 causal associations across 8,672 genes and 28 cell types), and 31 biomarker traits (spanning 681,480 causal associations across 16,085 genes and 28 cell types). By quantifying polygenic enrichment at both the single-cell and cell-type levels, we identify distinct immune cell contributions to both immune-related and systemic conditions. We demonstrate differential polygenic enrichment of Crohn's disease and COVID-19 amongst dendritic cell subtypes, and high activity of B cell interferon II response in SLE. Integration with clinical drug development data reveals that therapeutic compounds targeting gene-trait associations identified in this study are three times more likely to have secured regulatory approval. Using Crohn's disease as a motivating example, we demonstrate how population-based sc-eQTL data can pinpoint risk loci, effector genes and cell types, complementing findings from disease-focused tissue samples. Our findings provide a foundational resource for understanding the cell type-specific genetic architecture of disease and for guiding therapeutic discovery.

Introduction

Genome-wide association studies (GWAS) have identified thousands of loci associated with complex traits and diseases; yet, the majority of these signals reside in non-coding regions, complicating efforts to pinpoint causal genes and mechanisms[1]. Many non-coding variants act through gene regulatory mechanisms[2], influencing gene expression in a manner that is often highly cell type-specific[3–5]. This presents a significant challenge in pinpointing molecular mechanisms of diseases in heterogeneous tissues, where regulatory effects are often obscured in bulk transcriptomic analyses.

Single-cell genomics has transformed our understanding of gene regulation, revealing that the effects of genetic variation on gene expression can vary across different cell types and states. Consequently, single-cell expression quantitative trait loci (sc-eQTL) data have emerged as a promising avenue for identifying the cellular contexts in which genetic variants exert their effects. However, existing sc-eQTL studies have been underpowered[5], limiting their utility in causal inference of disease mechanisms.

Recent efforts to integrate GWAS data with single-cell transcriptomic atlases have highlighted disease-relevant cell types and programs. These approaches can be broadly categorised into two main types: those based solely on cell atlases[6] without consideration of genotypes, and those that incorporate genetic effects on single-cell molecular phenotypes[3,7–9]. Methods such as cell type enrichment scoring and topic modelling of gene expression patterns have linked regulatory programs to complex traits[10,11]. However, such approaches primarily establish correlation and do not directly assess whether genetically driven changes in gene expression causally contribute to disease risk. This distinction is particularly important in the immune system and complex tissues, where co-expression and linkage disequilibrium can confound signal interpretation.

In contrast, causal inference frameworks such as Mendelian randomisation (MR) test whether genetically-predicted gene expression has a directional effect on disease[12–14]. Owing to random allocation of genetic variants at conception and the fact that they remain fixed over the life course, sc-eQTL variants can be used as genetic instruments to predict gene expression. Under specific assumptions[12–14], these genetically-predicted gene expressions can be integrated with disease-specific genetic association estimates from GWAS through MR analysis, providing a platform to distinguish correlation from causation at cell type-specific and disease-specific resolution.

Here, we present a comprehensive framework for inferring causal gene–trait relationships by integrating sc-eQTL data from Phase 1 of the TenK10K project, which comprises matched whole-genome sequencing and single-cell RNA sequencing of over 5 million peripheral blood mononuclear cells across 28 immune cell types in 1,925 individuals. We applied MR using multiple sc-eQTL instruments to test the causal effects of 17,446 genes on 69 complex diseases

and 31 biomarker traits. This revealed gene–trait associations that are highly cell type-specific,
including many not detectable by comparable methods using GWAS data only and bulk-tissue MR
with whole blood eQTL instruments.

We further quantified polygenic enrichment across individual cells and cell types, identifying both
immune-related and systemic disease associations, including cancer, neuropsychiatric, and
cardiometabolic traits, with distinct cellular origins. We intersected these results with deep
learning-derived cell function scores to prioritise biological processes involved in the pathogenesis
of systemic lupus erythematosus (SLE). To explore the translational relevance of these findings,
we intersected our causal gene–trait map with clinical drug development data from the Open
Targets Platform[5]. We found that drugs whose targets matched our predicted gene–trait pairs were
three times more likely to achieve regulatory approval.

Finally, we demonstrate how these findings can be used to identify effector genes and new
therapeutic targets for Crohn's disease through triangulation of evidence from our study and an
independent study measuring changes in gene expression using single-cell dataset from patients.
Together, this study provides a population-scale, cell type-resolved map of causal effects of gene
expression on complex traits, offering a valuable resource for advancing mechanistic
understanding and therapeutic development.

Results

Landscape of causal associations between gene expression and complex traits across immune cells
We recently profiled the transcriptomes of 5,920,025 peripheral blood mononuclear cells (PBMCs)
collected from 1,925 donors as a part of the first phase of the TenK10K project[15]. These cells
encompassed 28 immune cell types and integration with matching whole genome sequencing
(WGS) data revealed 154,932 common variant sc-eQTLs (minor allele frequency > 1%) for 17,674
eGenes (genes with at least one *cis*-eQTL). The majority of eGenes exhibited cell-type restricted
effects, with only half of all identified eGenes being shared amongst at most a quarter of the cell
types[15], highlighting the importance of cell-resolved approaches for linking regulatory variants to
complex trait risk.

To quantify causal relationships between cell type-specific gene expression and complex traits, we
applied a multi-instrument summary data-based Mendelian randomisation (MR) framework using
sc-eQTL as proxies for gene expression[14] at the cell type level (**Figure 1a**). We compared this to
an alternative method that prioritises trait-associated genes directly from GWAS data (hereafter
referred to as GWAS genes) using gene-level aggregation of genetic association estimates with
MAGMA[16]. Analysis was restricted to genes expressed in at least one cell type and with at least
one significant *cis*-eQTL, for which corresponding variants were available across harmonised
GWAS summary statistics (**Methods**).

We tested 17,446 eGenes (including 12,873 protein-coding genes) across 28 immune cell types,
with a median of 5,948 eGenes (4,693 protein-coding) per cell type (**Figure 1b**, **Supplementary**
Table 1). For each gene-cell type pair, we estimated causal effects on 69 complex diseases and 31
biomarker traits spanning 10 categories (**Figure 1c**, **Supplementary Table 2**). This yielded
15,092,351 gene–cell type–trait combinations, of which 739,538 (4.9%) passed the discovery
threshold ($Q_{MR} < 0.05$ and heterogeneity in dependent instrument / HEIDI test $P_{HEIDI} > 0.01$).
Across disease traits, we identified 58,058 unique causal associations from combinations of 53
diseases, 28 cell types, and 8,672 genes (6,801 protein-coding). The median number of unique
genes with causal associations was 1,579 per cell type, 48 per disease, and 9 per cell type-disease
pair (**Supplementary Figure 1, Supplementary Table 3**). Across biomarker traits, 681,480
causal associations were identified from combinations of 16,085 unique genes (12,078 protein-
coding), 31 traits, and 28 cell types. The median number of unique genes with causal associations
was 4,891 per cell type, 6,078 per disease, and 710 per cell type-disease pair (**Supplementary**
Figure 2, Supplementary Table 3). Across the 28 immune cell types, the number of significant
MR gene-trait associations ranged from 2,133 for ILC cells to 51,149 for NK cells (median =
29,186). This count scaled linearly with the total number of MR tests performed per cell type
(**Supplementary Figure 3**), with a consistent proportion of significant results across cell types
(mean = 5.1%, SD = 0.3%). These findings establish a high-resolution, cell-type-specific map of
gene–trait relationships across the circulating immune system.

Trait-level insights from cell type-specific causal gene mapping
We identified 190,449 unique gene-trait associations in at least one cell type for 53 diseases and
31 biomarker traits. The number of significant MR-based gene associations per trait was strongly
correlated with the number of GWAS-prioritised genes identified using MAGMA (Pearson's $r =$
0.97), with an approximately exponential relationship between the two (**Supplementary Figure**
4). Of the 190,449 unique gene-trait associations identified by single-cell MR, 65,457 (34%) were
not identified by using MAGMA with GWAS data only, with a median of 44 (18%) per trait
(**Supplementary Figure 5**, **Supplementary Table 4**). Importantly, MR-identified associations
not detected by GWAS were more likely to be restricted to a small number of cell types (**Figure**
2a). A similar pattern was observed in comparison with bulk-tissue MR using genetic instruments
derived from whole blood eQTL from eQTLgen[17], wherein 115,762 (61%) gene-trait associations
were not identified (median = 209 / 64% per trait) (**Supplementary Figure 6**, **Supplementary**
Table 4). These comparisons underscore the added value of eQTL mapping at single-cell
resolution for identifying effector genes with cell type-specific roles in complex traits.

172
Figure 1 | Study design and causal inference using single-cell eQTLs.
a) Overview of study design. We integrated single-cell eQTL data from 5 million peripheral blood mononuclear cells (PBMCs) (covering 28 immune cell types) profiled in the TenK10K Phase 1

cohort (1,925 donors) with GWAS summary statistics for 100 complex traits (69 diseases and 31
biomarkers) using a multi-instrument Mendelian randomisation (MR) framework. **b**) Number of
eGenes (genes with at least one significant cis-eQTL) included in the MR analysis per cell type,
stratified by gene type (protein-coding vs non-coding). Median of 5,948 eGenes per cell type. **c**)
Number of trait-associated genes identified using GWAS summary statistics alone via MAGMA
(FDR < 5%) across the 100 traits. Each point represents a trait; the point size reflects the effective
sample size of the GWAS, and the colour indicates the trait category (e.g., immune, cancer,
cardiometabolic).
184
In addition to identifying causal genes, MR also helps in resolving the causal effect direction on
trait outcomes, providing critical information to distinguish between targeting upregulation and
downregulation of gene expression in drug design. Across all significant MR associations in our
study, the direction of effect was evenly split between positive (n=369,155) and negative
(n=370,383), indicating a balanced contribution of activating and repressing regulatory effects on
trait outcomes (**Figure 2b**). This symmetry was consistent across both phenotype categories and
cell types, implicating that disease-relevant gene networks involve a balance of activation and
inhibition.
193
Across trait categories, traits closely related to peripheral blood composition yielded the highest
number of associations, including 163,383 unique gene-trait associations across 26 blood
biomarker traits. Substantial numbers of associations were also detected for cancer-related traits
(5,375 associations across 20 traits), and immune-mediated diseases (2,943 associations across
nine traits) (**Figure 2b**). Polygenic traits with large GWAS sample sizes also showed strong MR
signals, including type 2 diabetes mellitus (5,608 associations), estimated heel bone mineral
density (7,982 associations), and schizophrenia (1,033 associations) (**Figure 2c**, **Supplementary
Table 3**). These associations were spread across immune cell types, but correlated with the number
of eGenes identified from the sc-eQTL mapping (**Supplementary Figures 1-2**). Similar patterns
of the relative number of MR genes across cell types were observed amongst top-associated traits
in each category (**Figure 3c**). These findings imply that context-specific gene expression in
PBMCs may play a causal role in complex traits beyond immune-related traits, or that these cells
share a similar genetic regulation of gene expression with trait-relevant cell types in other tissues.

207
208 **Figure 2 | Cell type-specific causal gene-trait associations across complex traits.**

a) Distribution of gene-trait associations with MR evidence by the number of cell types in which the association is detected. Left y-axis: total number of gene–trait pairs (bars). Colours distinguish associations identified by MR only versus those also supported by GWAS ($Q_{MAGMA} < 0.05$). Right y-axis: proportion of MR-significant associations also supported by GWAS (red line and points). **b)** Number of significant gene-trait pairs identified by Mendelian randomisation (MR) across trait categories. Associations are defined as $Q_{MR} < 0.05$, $P_{HEIDI} \geq 0.01$. Bar color indicates the direction of association (positive or negative) with an increased gene expression. **c)** Same as panel b, but for comparison against results from MR using eQTL derived from bulk whole blood expression data from eQTLgen consortium. **d)** Bar charts showing number of genes with MR associations (MR genes) by cell types across selected 48 traits (out of 100 tested). The traits are displayed in subpanels within a grid (8 rows, 6 columns) and ordered row-wise in descending order by number of unique MR genes as displayed on the top-right corner of each trait subpanel, with a background coloured by trait category. Only traits with the top 10 highest number of unique MR genes per category and with 10 or more unique MR genes are displayed. The full results are presented in **Supplementary Figures 8-9**.

Polygenic enrichment reveals trait-relevant immune cell types and gene programs

To identify the immune cells involved in the genetic architecture of complex traits, we performed a polygenic enrichment analysis using the single-cell Disease Relevance Score (scDRS) framework[10]. We analysed 100 traits across the 28 immune cell types profiled in Phase 1 of the TenK10K study by computing cell-level scDRS score at cell-level, and statistics for polygenic enrichment at both cell-level and cell type-level using the default scDRS permutation scheme. To control for differences in cell abundance, we randomly sampled up to 10,000 cells per cell type, yielding a dataset of 229,239 cells.

We quantified the proportion of phenotype-enriched cells (cell-level $P_{scDRS} < 0.05$) within phenotype-enriched cell types (cell-type-level $P_{scDRS} < 0.05$) for each trait (**Figure 3a, Supplementary Table 5**). All 28 cell types showed enrichment for at least one phenotype (mean = 14.6 traits per cell type), with cDC1 (40 traits), cDC2 (37 traits), and CD4 proliferating T cell (33 traits) showing the strongest polygenic enrichment (**Supplementary Figure 7**). In total, 95 of 100 traits were enriched in at least one cell type (mean = 4.1, max = 10). Immune-mediated diseases showed the highest number of enriched cell types, as expected; for example, multiple sclerosis was enriched in 10 cell types. We also observed enrichment of non-immune polygenic traits, including estimated heel bone mineral density (9 cell types), Alzheimer's disease (7), and schizophrenia (7).

At single-cell resolution, the proportion of enriched cells per trait ranged from 8% and 79% (median = 18.9%) (**Figure 3a**). The strongest enrichment was observed for a negative antibody response to the first dose of the COVID-19 vaccine (no antibody detected post-vaccination), where 79% of cells were significantly associated with the trait, but predominantly enriched in antibody-producing B cells. As expected, monocyte count traits were enriched in CD14+ and CD16+ monocytes, and lymphocyte count traits in T cell subsets. Notable examples also included

enrichment of systemic lupus erythematosus in B cells; lung and breast cancers in proliferating
cells, and coronary artery disease and Alzheimer's disease in monocytes (**Figure 3a**). These
findings suggest that complex trait-associated variants, including those not traditionally linked to
immune function, can affect gene expression patterns across diverse immune cell types.

Using Crohn's disease as a case study, we identified 10,741 out of 46,920 sampled cells (23%) as
enriched for polygenic signals across seven cell types (**Figure 3b**). The most enriched cell types,
ranked by Z_{scDRS} statistics, were cDC2, MAIT, cDC1, ILC, ASDC, CD4 TEM, and NK CD56[bright]
cells. Enrichment proportions ranged from 9.2% in CD4+ TEM to 54.3% in cDC2 (**Figure 3c**).
Dendritic cells, particularly cDC2 and cDC1, showed the strongest enrichment. These results are
consistent with prior reports of dendritic cell infiltration and activation in Crohn's-affected
intestinal tissue[18], including overexpression of chemokine receptors involved in T cell recruitment.
We also observed enrichment in ASDCs, a less-characterised dendritic subset with unclear roles
in autoimmunity[19]. In contrast, plasmacytoid dendritic cells (pDCs) did not show enrichment for
Crohn's disease but were the only dendritic subtype enriched for COVID-19 hospitalisation
(**Figure 3d)**, consistent with their established role in antiviral immunity and type I interferon
production[20].

The polygenic enrichment analysis also facilitates the identification of trait-related cell functions
through integration with scDeepID, an in-house deep learning method to quantify cell function as
cell states at single-cell resolution (see **Methods**). Using B cells in Systemic Lupus Erythematosus
(SLE) as an example, we leveraged scDeepID to compute 400 representative cell function scores
in 539,820 B cells (including B naive, B intermediate, and B memory cell types) identified in the
TenK10K phase 1 study. We extracted cell function scores for the 30,000 sampled B cells used in
the scDRS analysis, and compared the average cell function scores between 17,264 SLE-enriched
cells (cell-level $P_{scDRS-SLE} < 0.05$) and 12,736 non-SLE-enriched cells using a one-sided T-test. We
identified 202 cell functions with a higher average score in the SLE-enriched cells compared to
non-SLE-enriched cells at $Q < 0.05$ (**Supplementary Figure 8, Supplementary Table 6**). The
cell functions with the highest mean score difference based on Q value include cellular response
to type II interferon, positive regulation of inflammatory response, tumour necrosis factor-
mediated signalling pathway, biological process involved in interaction with host, and leukocyte-
mediated cytotoxicity (**Supplementary Figure 9a-b)**. The scores of these five cell functions also
showed a trend of linear increase across deciles of scDRS$_{SLE}$ (**Supplementary Figure 9c**),
implicating involvement of these pathways and their gene members in the pathogenesis of SLE.

To assess the robustness of our sampling strategy, which oversampled rare cell types, we
conducted a sensitivity analysis using proportional sampling (10% of cells per cell type)
(**Methods**). Both the distribution of cell-level scDRS scores and the proportion of phenotype-
enriched cells remained consistent (**Supplementary Figures 10-11**), confirming that enrichment
patterns were not artefacts of oversampling.

Figure 3 | Polygenic enrichment of complex traits across immune cell types.

a) Average proportion of phenotype-enriched cells across 100 complex traits, stratified by immune cell types. Enrichment was calculated using the single-cell disease relevance score (scDRS); cells were considered enriched if their scDRS $P < 0.05$ and belonged to cell types with significant trait enrichments (cell-type-level $P_{scDRS} < 0.05$). **b.** UMAP embedding of 229,236 sampled peripheral immune cells, coloured by scDRS score for Crohn's disease. Only cells from the seven cell types with significant enrichment (cell-type level $P_{scDRS} < 0.05$) are coloured; all other cells are shown in grey. **c.** Distribution of scDRS scores for Crohn's disease across the 28 immune cell types. Cell types are ordered by scDRS Z-score, and those with significant enrichment ($P_{scDRS} < 0.05$) are highlighted in red. **d.** Mean scDRS score across deciles of cell-level scDRS for COVID-19 and Crohn's disease across four dendritic cell subtypes (cell type-level $P_{scDRS} < 0.05$). Cell types without evidence of enrichment ($P_{scDRS} \geq 0.05$) are faded out, demonstrating contrasting enrichment patterns across diseases and dendritic cell subsets.

Single-cell MR supports drug target discovery and clinical translation

Recent studies have shown that drugs supported by human genetic evidence are more likely to advance through the drug development pipeline and gain regulatory approval[21,22]. Single-cell transcriptomics can further refine target validation by resolving cell type specificity within disease-relevant contexts[23]. Since most drug targets are proteins encoded by genes, the cell-resolved causal associations uncovered by our sc-eQTL MR framework may offer novel insights into tractable therapeutic mechanisms.

To evaluate this, we cross-referenced our MR results with curated drug development data from the Open Targets Platform[24] (version 25.06). First, we focused on 12,873 protein-coding genes tested in the MR analysis and 57 diseases with at least one matching indication available in the Open Targets, yielding 733,761 possible gene-indication pairs, hereafter the target-indication universe. Of these, 13,196 pairs (1.8%) were supported by MR evidence in at least one cell type (**Methods**). According to drug development activity data (from ChEMBL[25]), 6,712 target–indication pairs (involving 853 targets and 56 indications) have been investigated in clinical trials. Among these, 174 pairs (2.6%) were supported by our MR analysis. Notably, 473 of the 853 clinically tested targets (55%) had MR support for at least one indication in our dataset, including 151 targets that have received regulatory approval (**Figure 4**, **Supplementary Table 7**). MR-supported target–indication pairs were more likely to be observed across all stages of clinical development (**Figure 4b**, **Supplementary Table 8**), with approved indications showing the highest enrichment. Overall, MR-supported pairs were 3.3 times more likely to reach regulatory approval than unsupported pairs (odds ratio = 3.3; lower 95% CI: 2.41; $P = 7.1 \times 10^{-9}$, one-sided Fisher's exact test).

To further validate this association, we compared Open Targets evidence scores for drug–indication pairs with and without MR support. The Open Targets score is a normalized metric (0–1) derived from diverse evidence sources, including genetic associations, somatic mutations, expression data, animal models, and literature mining (**Methods**). Pairs supported by MR showed significantly higher evidence scores overall (mean = 0.37 vs. 0.26; $P = 2.3 \times 10^{-9}$; **Figure 4c, Supplementary Table 9**). Stratifying by evidence type, we found stronger support for MR-backed

336 pairs in both genetic evidence (mean = 0.52 vs. 0.42; $P = 7.7 \times 10^{-3}$) and non-genetic sources (mean
337 = 0.38 vs. 0.33; $P = 6.3 \times 10^{-3}$), with a more pronounced effect in the genetic category.
338
Next, we assessed the concordance between the direction of MR effect and the mechanism of
action (MoA) of drugs at the most advanced clinical development stage for each target–indication
pair (**Figure 4d, Supplementary Table 10**). On average, MR-supported pairs more often showed
concordant MoA, for instance, risk-increasing (positive effect) MR results aligning with inhibitors,
or protective (negative effect) results aligning with agonists. This pattern was especially
pronounced for drugs in Phase III trials or with regulatory approval. Moreover, MR-supported
targets in later development stages were associated with stronger evidence of causal effect (**Figure
4e, Supplementary Table 10**).
347
Finally, we examined selected examples from the 174 MR-supported target–indication pairs
(covering 131 genes and 25 diseases) in more detail (**Figure 4f, Supplementary Figure 12,
Supplementary Table 10**). These included several known immune targets of approved therapies:
JAK2 and TNF for Crohn's disease, IL6R for rheumatoid arthritis, and IL23A and IL17RA for
psoriasis. Importantly, our analysis also identified high-confidence targets in diseases not
classically associated with immune dysfunction, including APP (amyloid precursor protein) for
Alzheimer's disease and GLP1R (glucagon-like peptide-1 receptor) for type 2 diabetes.
355
APP encodes a precursor to Amyloid-β peptides, whose aggregation forms amyloid plaques linked
to synaptic dysfunction and cognitive decline in Alzheimer's disease[26]. GLP-1R, a receptor
primarily expressed in the pancreas and brain, modulates insulin secretion and glucose metabolism
through binding to GLP-1 proteins[27]. Initially developed for diabetes, GLP-1R agonists (e.g.,
semaglutide) have recently shown efficacy in reducing cardiovascular risk[28] and promoting weight
loss[29] in individuals without diabetes. These examples highlight how cell type-specific MR results
can identify therapeutically actionable targets across complex diseases including cases where the
encoding genes are primarily expressed in other tissues, potentially due to shared genetic
regulation.

365
366 **Figure 4 | Single-cell MR supports drug target validation and clinical development success.**
367 **a)** Number of protein-coding gene targets with MR support ($Q_{MR} < 0.05$; $P_{HEIDI} \geq 0.01$) across
368 clinical development stages, as defined by target–indication pairs in the Open Targets Platform
369 (OTP). Bars are grouped by the maximum development phase for each pair. **b)** Enrichment of MR-

supported target–indication pairs among clinically investigated indications. Odds ratios and lower 95% confidence intervals are shown for pairs with versus without MR support, stratified by maximum clinical development phase. Right-side annotations indicate counts of MR-supported target–indication pairs over the total number of clinically investigated pairs per phase. **c)** Distribution of OTP evidence scores for target–indication pairs with and without MR support. Scores are shown for all evidence sources (overall), as well as genetic and non-genetic sources separately. **d)** Number of MR-supported target–indication pairs, stratified by predicted direction of MR effect (positive or negative) and mechanism of action (MoA) of drugs with the highest OTP evidence score. Data are grouped by maximum clinical development stage. **e)** Strength of MR evidence ($-\log_{10} P_{MR}$) for target–indication pairs across clinical development stages. **f)** MR-supported targets for five selected diseases. Each bar represents a target–indication pair, ordered by OTP overall association score and coloured by maximum clinical development phase. The top five targets by OTP score are labelled.

Single-cell genetics reveals causal cell-type-specific mechanisms in Crohn's disease

To illustrate the added resolution of single-cell MR, we present a focused case study of Crohn's disease—a chronic inflammatory disorder of the gastrointestinal tract characterised by disrupted epithelial integrity, microbial dysbiosis, and dysregulated immune signalling[30,31]. Genetic studies have implicated immune-related genes and pathways involved in autophagy, cytokine signalling, and endoplasmic reticulum stress in disease pathogenesis[32].

Using our single-cell MR framework, we identified 1,791 gene-cell type pairs and 510 unique genes (407 protein coding) with evidence of a causal relationship with Crohn's disease across 28 immune cell types (**Supplementary Figure 13**). Of these, 88 were not detected using MAGMA-based gene prioritisation from GWAS data alone, and 339 were not identified using bulk whole blood-based MR (**Supplementary Figure 14**). A total of 209 genes (163 protein-coding) exhibited cell-type-specific MR associations, defined as significant in only one cell type. Notably, 146 (71%) of these were not detected in bulk-tissue whole blood MR, highlighting the unique resolution provided by single-cell approaches (**Supplementary Table 11**). Of the 1,791 gene-cell type pairs with MR evidence, between 66 to 1,076 pairs were also causally associated with other immune diseases (in descending order of shared signals: inflammatory bowel disease, ulcerative colitis, psoriasis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and eczema), potentially revealing shared causal molecular pathways. Of the 1,791 gene-cell type pairs with MR evidence, 232 (13%) demonstrate discordant directions of effect between diseases, highlighting disease context-dependent causal effects (**Supplementary Table 12**).

As a proof-of-principle, we recovered known therapeutic targets for Crohn's disease, including *TNF*, *IL23R*, and canonical risk genes such as *ATG16L*, *NOD2*, and *IRGM* (**Supplementary Table 13**, **Figure 5a**). Interestingly, we observed divergent directions of causal effect for 61 genes (20%), where the same gene exhibited opposing MR directions in different cell types. For example, *NCF4* (which encodes a component of an enzyme complex in phagocytes), showed a positive effect in B memory cells but a negative effect in B naive cells (**Figure 5b**), suggesting context-specific

412 regulatory roles. The negative effect of *NCF4* in B naive cells is also observed in eczema.
413 Interestingly, while the positive effect of *NCF4* in B memory cells is also observed in psoriasis, it
414 has a negative effect in multiple sclerosis (**Supplementary Table 12**).
415
To validate the biological relevance of our findings, we compared MR-identified genes with
differentially expressed genes from single-cell RNA-seq of colon biopsies from 46 patients with
Crohn's disease and 25 healthy controls[33]. While some intestinal immune cells are tissue-resident,
many cell type lineages, such as B cells, T cells, dendritic cells, and NK cells, are shared between
peripheral and tissue compartments. We harmonised cells between datasets by major cell types,
excluding tissue-specific subsets such as macrophages (**Supplementary Figure 15**), and
examined the consistency of MR directionality with differential expression.
423
We reasoned that genes with a positive MR effect (*i.e.*, risk-increasing) would be upregulated in
disease tissue, whereas those with a negative MR effect (protective) would be downregulated. We
identified a total of 116 genes with matched major cell types. Of these, 62 genes had concordant
direction of effect between MR and DEG, 47 with discordant effects and 7 with both concordant
and discordant effects, depending on concordance between and within major cell types
(**Supplementary Table 14, Supplementary Figure 16**). We highlight *ZBTB38* as an interesting
example with convergent : it showed a positive MR effect and was upregulated in B cells, CD4+
T cells, and CD8+ T cells from Crohn's disease colon samples (**Figure 5c**). Conversely,
TNFRSF18 (a known immune modulator) showed a protective MR effect but was also upregulated
in CD4+ T cells from Crohn's disease colon, suggesting potential compensatory mechanisms due
to reverse causation (**Supplementary Table 14, Supplementary Figure 16**).
435
436 Together, these results demonstrate how single-cell MR can identify both established and
437 uncharacterised causal genes with cell-type-specific effects, refine interpretation of differential
438 expression studies, and inform mechanistic hypotheses for complex disease biology.

439
Figure 5 | Cell-type-specific causal and transcriptional signatures in Crohn's disease.

a) Selected MR-significant genes in Crohn's disease, shown as $-\log_{10} P_{MR}$ multiplied by direction
of MR estimate of the lead instrument. Only protein coding genes are shown. A positive direction
denotes increased disease risk with increased expression, and negative direction denotes reduced
disease risk for increased expression. Gene categories include canonical risk genes, approved drug
targets and their pathways (combined), and differentially expressed genes in matched major cell
types of colon immune cells of Crohn's disease patients (DEGs) with concordant direction of effect
(See **Methods** and **Supplementary Table 12**). Genes denoted with an asterisk are both canonical
or drug target genes and DEGs. DEGs were identified from colon biopsy scRNA-seq data (Kong
et al., 2023)[33] by matching genes and major immune cell types with MR results. Empty grids
indicate the gene was not an eGene in that cell type and was therefore not tested. Black outlines
denote MR associations ($Q_{MR} < 0.05$; $P_{HEIDI} > 0.01$). **b)** Causal effect plots showing GWAS effect
sizes (*y*-axis) against cell type-specific sc-eQTL SNP effect sizes (*x*-axis), paired with locus zoom
plots for selected genes. Data points in both plots represent common genetic variants in the *cis*-
region of the gene that are available in both GWAS and sc-eQTL datasets. Variants used as
instruments for gene expression in the MR analysis are highlighted in red, and lead instruments
(lowest sc-eQTL *P*) are circled in purple. The slope in the effect plot corresponds to the point
estimate of the MR effect size (coefficient) of the lead instrument. Row 1 and 2, respectively:
positive causal effect of *NCF4* in B memory cells and negative causal effect of *NCF4* in B naive
cells; Row 3: positive causal effect of *ZBTB38* in CD4+ naive cells. **c)** Colon immune cells from
Kong et al., 2023, colour-coded by major cell type annotations derived by mapping major cell
types with the TenK10K study (see **Methods, Supplementary Table 16**). Unmatched major cell
types are excluded (original annotations of the full datasets are presented in **Supplementary**
Figure 16). **d)** Expression of *NCF4* and *ZBTB38*, which both have causal effects on Crohn's
disease in circulating immune cells and differential expression in colon immune cells. Colon
immune cells are projected on the UMAP coordinates from panel c, stratified by disease and
inflammation status.
467
468 **Discussion**
469
By integrating population-scale sc-eQTL data from 1,925 individuals in the TenK10K cohort with
genome-wide association study (GWAS) results, we generated a comprehensive map of cell type-
specific causal gene–trait relationships across 28 peripheral immune cell types and 100 complex
traits. Using a multi-instrument Mendelian randomisation (MR) framework, we identified over
8,000 genes with evidence of causal association with at least one disease, and over 16,000 with at
least one biomarker. In total, this resulted in 190,343 unique gene–trait associations, spanning
739,538 gene–trait–cell type combinations. These findings align with the postulated genetic
architecture of complex traits, where trait-associated variants are numerous, context-specific, and
distributed across diverse regulatory programs[34,35]. Given that genes and variants exhibit
pleiotropic effects[36], and that diseases may share causal molecular aetiology[37], this cell type-
resolved causal association map provides a platform for prioritising fundamental mechanisms
underlying complex traits.
482
Approximately one-third (34%) of gene–trait associations identified through MR were not
recovered using conventional gene-based GWAS approaches (*e.g.*, MAGMA), and the majority

of these were specific to a single or small number of cell types. This underscores the value of cell-
resolved sc-eQTL data for uncovering regulatory effects that are masked in bulk tissue analyses.
Notably, we found that 61% of the gene-trait associations identified in our study were undetectable
in a comparable MR analysis using genetic instruments derived from bulk-tissue eQTL mapping
of whole blood sample from eQTLgen[17], despite having 16 times larger sample size for eQTL
discovery. These findings affirm the hypothesis that cell-specific genetic regulations are
undetectable in aggregated datasets, further reinforcing the utility of single-cell resolved eQTL
mapping.
493
While our analysis focused on PBMCs, we identified causal associations not only for immune-
related diseases and blood traits, but also for systemic traits such as type 2 diabetes, schizophrenia,
cancer, and bone mineral density. These results potentially suggest that peripheral immune cell
dysregulation is directly involved in the pathogenesis of systemic diseases, or that they may share
cell-level genetic regulation with other cell types in disease-relevant tissues. These two hypotheses
can be observed in the polygenic enrichment patterns observed in the single-cell disease relevance
score (scDRS) analysis, which shows that polygenic signatures of systemic disease were indeed
observed across PBMC cells, but to a lesser extent compared to traits directly related to immune
dysregulation and peripheral blood composition. Given that nearly half of cis-eQTLs are shared
across tissues[20], these findings implicate that large-scale sc-eQTL maps may provide some insights
into causal biology of systemic diseases in other tissues with similar expression of disease-relevant
genes or with shared genetic regulation.
506
At the cell type level, we found striking enrichment of immune-mediated disease associations in
dendritic cell (DC) populations. In Crohn's disease, for example, multiple DC subsets (cDC1,
cDC2, ASDC) showed strong polygenic enrichment and MR-supported causal associations,
consistent with prior evidence that DCs accumulate and become activated in inflamed intestinal
tissue[9]. In contrast, COVID-19 genetic risk was specifically enriched in plasmacytoid DCs (pDCs),
aligning with their established role in antiviral immunity and rapid interferon production[11].
Focusing on B cells in the context of SLE, we found SLE-enriched cells display significantly a
higher cell function score for cellular response to type II interferon, a B cell-intrinsic mechanism
implicated in SLE pathogenesis via autoimmune response due to dysregulated germinal centre[38].
These findings suggest that large-scale sc-eQTL data, when integrated with GWAS and functional
annotation of relevant biological context, can resolve the cell type-specific contributions of
immune populations to disease even in the absence of disease-context tissue sampling.
519
Translationally, our data show that causal gene–trait relationships derived from single-cell MR are
predictive of clinical development success. By intersecting MR results with drug target and trial
data from the Open Targets Platform, we found that target–indication pairs supported by single-
cell MR were 3.3 times more likely to reach regulatory approval. These pairs also showed higher
evidence scores across both genetic and non-genetic data sources and were more likely to display

concordant direction of effect with the mechanism of action of approved or late-phase drugs. Our
framework successfully recapitulated known therapeutic targets, including *JAK2* and *TNF* for
Crohn's disease, *IL6R* for rheumatoid arthritis, *APP* for Alzheimer's disease, and *GLP1R* for type
2 diabetes, while nominating cell type-specific genes with strong genetic support for new
indications. In addition, our data show more than half of targets tested in clinical trials (including
151 that are already approved) had single-cell MR support for at least one tested indication,
implicating opportunities for drug repurposing.
532
To highlight the utility of cell-type-resolved MR for identifying both canonical and novel
therapeutic targets, we further explored 510 genes associated with Crohn's disease as a case study.
We identified 510 MR-significant genes, including those with well-established roles such as
NCF4, *ATG16L1*, and *IL23R*, as well as less characterised candidates such as *ZBTB38*. The
transcriptional repressor *ZBTB38* exhibited a positive causal effect in T and B cell subsets and was
independently upregulated in disease-affected colon tissue. *ZBTB38* has been linked to Crohn's
disease[39] and other inflammatory diseases[40,41], however its functional role in T and B cells has not
been explored. Our findings here offer a testable hypothesis that *ZBTB38* may modulate cell type-
specific programs relevant to disease pathogenesis, supported by differential expression in disease.
A second example, *NCF4,* is a known risk gene that encodes a subcomponent of the NADPH
complex, playing a critical role in oxidative stress and antimicrobial function[42]. In Crohn's disease,
NCF4 exhibited a positive effect in B memory cells, in contrast to a negative effect in other cell
types including B naive cells. Interestingly, independent eQTL data show that the top eSNP in B
memory cells, which has a uniquely positive effect, is a fine-mapped SNP with a negative eQTL
effect in monocytes, macrophages, neutrophils, but a positive splicing QTL (sQTL) effect in B-
cell derived lymphoblastoid cell lines[24,43]. Many eQTL effects are explained by splicing QTLs[44,45],
and these results highlight the need for long-read sequencing to resolve cell type specific sQTLs
and explain novel causal associations. In this case study, we form links between MR results within
diseases as well as independent, orthogonal sources of evidence such as differential gene
expression[46].
553
We also identified MR-supported associations that may inform mechanisms of action for existing
therapies. For example, for Crohn's disease, we found a positive causal association of *IL23R* in γδ
T cells and a negative (protective) association of *IL12Rβ2* in multiple immune cell types, while
IL12Rβ1 showed no significant effect. These observations are consistent with clinical evidence
that ustekinumab (targeting the shared *IL12/IL23* p40 subunit, blocking the *IL23R/IL12Rβ1*
receptor complex) acts predominantly through *IL23* blockade, and may help explain the increased
efficacy of *IL23*-specific therapies like guselkumab[47–49]. Our data suggest that targeted modulation
of *IL23R* and sparing of *IL12RB2* may optimise therapeutic efficacy while reducing off-target
effects.
563

Our study has several limitations. First, MR estimates are subject to bias from overestimation in
sc-eQTL discovery (winner's curse) and residual pleiotropy not fully accounted for by the HEIDI
test. Second, PBMCs may not capture causal regulation in disease-relevant tissues or tissue-
resident immune compartments. Third, the statistical power of our study may be limited for rare
cell types genes with low expression. While we downsampled abundant cell types to reduce bias
in the polygenic enrichment analysis, sensitivity analyses suggest this had minimal impact.
Furthermore, OpenTargets may not capture all active drug development programs, and many
apparently negative results may reflect the absence of evidence rather than evidence of absence.
Depending on the particular disease, signals may not be detected if their key causal effects are
mediated in non-peripheral immune cells, or tissue-specific cells such as epithelial or stromal cells.
Finally, functional validation of hypotheses is essential to confirm the causal relevance of newly
implicated genes and their therapeutic potential.
576
In summary, we present a large-scale, cell type-resolved atlas of causal gene–trait associations by
integrating single-cell eQTL mapping with GWAS through Mendelian randomisation. Our results
highlight extensive and cell-specific polygenic contributions to complex traits, identify new
regulatory mechanisms in disease, and demonstrate that MR-informed cell type-specific targets
are predictive of drug development success. This resource provides a powerful foundation for
understanding the molecular underpinnings of complex disease and for guiding precision
therapeutic strategies.
584
585 **Methods**
586
Data sources
Single-cell eQTL
To perform single-cell MR analysis, we used genetic instruments derived from a large-scale single-
cell expression quantitative trait loci (sc-eQTL) association analysis from Phase 1 of the TenK10K
project[15]. This dataset comprises matched whole-genome sequencing (WGS) and single-cell RNA-
sequencing (scRNA-seq) data from 1,925 individuals of European ancestry from Tasmanian
Ophthalmic Biobank (TOB) and the BioHEART study cohort, covering over 5 million peripheral
blood mononuclear cells (PBMCs) across 28 immune cell types. The cell types were identified
using a combined approach that uses scPred[50] and sc-HPL[51] with Azimuth PBMC reference
dataset[52].
597
The sc-eQTL association test was performed separately in each of the 28 cell types using a Poisson
mixed model for single-cell counts implemented in SAIGE-QTL[53] with the following covariates:
sex and age of the individuals, 7 genotype PCs, 5 cell type-specific expression PCs, cohort status
(TOB or BioHEART), percentage of counts from mitochondrial genes and total counts. For each
gene, common genetic variants (minor allele frequency >1%) within *cis*-region of the gene, defined
as 100 kbp window upstream and downstream site of the tested eGene bodies based on ENCODE

v44 hg38 coordinates, were tested for association with expression level of the gene measured in
raw counts. A total of 12,874,224 variants were included in the analysis, which yielded 154,932
common variant sc-eQTL across 17,674 unique eGenes across cell types at FDR 5%.
607
Genome-wide association study of complex traits
To perform MR, MAGMA and scDRS, analyses, we used publicly accessible genome-wide
association results of 100 complex diseases and biological traits across 10 phenotype categories:
Blood (26 traits)[54], Skeletal traits (5 traits)[55], Cancer (31 diseases)[56–65], Immune (9 diseases)[66–72],
Viral infection (6 diseases)[73–75], Cardiometabolic (6 diseases)[76–82], Neurologic (3 diseases)[83–85],
Psychiatric (7 diseases)[86–90], Respiratory (3 diseases)[91–93], and Other (4 diseases)[94–97]. For each
trait, we obtained GWAS summary statistics from public repositories.
615
Summary statistics were harmonised to the TenK10K study by matching variants' genomic
coordinates and alleles, performing conversion to hg38 with liftOver and harmonisation of minor
and major alleles based on allele frequency in individual-level genotype from the TenK10K study.
To ensure consistency of variants' allele frequency and linkage disequilibrium pattern with
TenK10K sc-eQTL dataset, analysis was limited to GWAS performed in European ancestries. If
unreported in the GWAS summary statistics, values such as the beta value as log(OR), standard
error and p-values were derived from other reported values. The effective GWAS sample size for
binary disease traits presented in **Figure 1c** was calculated as 4 / (1/number of cases + 1/number
of controls). More details of each trait, GWAS data source, reference, and number of samples are
provided in **Supplementary Table 2**.
626
Mendelian randomisation analysis
To identify genes associated with disease and biomarker traits in PBMC cell types, we performed
a multi-instrument Mendelian randomisation (MR) analysis using the SMR approach as
implemented in the SMR v1.3.1 software package[13]. Genetic instruments for MR were selected
from common variants within the *cis*-region of the tested gene bodies passing cell type-specific
thresholds. The cell type-specific thresholds were derived from the maximum *P*-value across sc-
eQTL for eGenes identified at FDR <5% in the TenK10K phase I study[15]. Following the default
parameter of the SMR software[14], variants that are not available in the GWAS summary statistics
of tested phenotype or those with allele frequency difference > 0.2 are excluded prior to the
instrument selection steps. In the MR analysis, we pruned variants that are highly correlated
(linkage disequilibrium (LD) r^2 > 0.9) with the top sc-eQTL within the region, and used set-based
approximation accounting for residual LD to combine MR estimates from the remaining variants,
with *P*-value derived using Saddlepoint approximation. MR analysis was performed by modelling
the effect of increased gene expression level on disease risk or trait levels so that a positive
association implies a trait-increasing (or risk-increasing) effect and a negative association implies
a trait-decreasing (or protective) effect.

To adjust for multiple testing, MR *P*-values were adjusted for false discovery rate (FDR) by
calculating *Q*-values based on *P*-values distribution across cell type-gene combinations per trait
with the *qvalue* R package[98]. To minimise confounding by pleiotropic effects on other genes, we
further performed a test for heterogeneity in dependent instruments (HEIDI)[13] for each MR test
we performed. An MR estimate with a $Q < 0.05$ and a $P_{HEIDI} \geq 0.01$ were considered as evidence
of a causal association.
649
650   The comparison with eQTLGen was performed using publicly available pre-formatted SMR
651   summary statistics from eQTLgen Consortium[17], downloaded from https://eqtlgen.org/cis-
652   eqtls.html. Consistent with the original publication, we used a threshold of $P_{eQTL} < 2.02 \times 10^{-5}$ to
653   select a genetic instrument for MR. Multiple testing correction for MR was performed consistently
654   with the TenK10K study.
655
Identification of GWAS genes
To identify GWAS genes for comparison with MR results, we performed a gene-level aggregation
of single-variant estimates from GWAS summary statistics using MAGMA[16]. The aggregation for
each gene was performed across variants within the transcription start and end sites of the gene
(based on ENCODE v44 hg38 coordinates) using a SNP-wise model with linkage disequilibrium
between variants modeled using reference data TenK10K phase I individual-level genotype. *P*-
value for a gene-trait association was derived using mean chi-squared statistics by approximation
of known sampling distribution. To account for multiple testing, we calculated Q-values across all
analytical sets. Genes associated with a trait at $Q < 0.05$ were considered as putative GWAS genes
for the trait.
666
Single-cell polygenic enrichment of complex traits
We utilized the single-cell disease relevance score (scDRS)[10] method to quantify polygenic
enrichment of complex traits at both individual-cell and cell-type levels. scDRS integrates single-
cell gene expression profiles with GWAS summary statistics to associate individual cells to the
GWAS trait, by testing overexpression of trait-relevant genes derived from GWAS in a given cell
relative to other genes with similar expression profile across all cells. To run scDRS for each trait,
we first extracted the top 1,000 trait-associated genes based on *Z*-score derived from the MAGMA
analysis. Next, we used scDRS to compute the aggregate expression of the associated genes in
each cell, weighted by the GWAS MAGMA *Z*-score and inversely weighted by gene-specific
technical covariates in the single-cell data, using the mean-variance model. To compute cell-level
P-value for overexpression of trait-relevant genes, we followed scDRS method to first generate
1,000 sets of cell-specific raw control scores computed using Monte Carlo (MC) samples of
matched control gene sets (matching gene set size, mean expression and expression variance of
the selected genes). The *P*-value was then derived by comparing normalised trait scores against
normalised control scores based on the empirical distribution of the pooled normalised control
scores across all control gene sets and all cells.

Single-cell RNA sequencing data to perform scDRS analysis were extracted from ~5 million
PBMCs that passed through the processing and quality control pipeline in the TenK10K phase I
study[15]. The cell-level scoring in scDRS was performed using sex, age, number of genes, and
cohort (TOB and BioHEART) as covariates. To manage computational efficiency and account for
variations in cell type proportions, we randomly sampled a maximum of 10,000 cells for each of
the 28 immune cell types in the TenK10K phase 1 study, resulting in 229,239 total sampled cells.
To test the robustness of this sampling strategy, we repeated this procedure using Crohn's disease
as an example with an alternative sampling strategy by taking 10% of cells from each cell type.
691

Quantification of cell function score in B cells
We computed cell function scores in B cells as cell states using scDeepID, a flexible multi-task
transformer that leverages different biological pathway databases as guides to train the model.
First, we trained a scDeepID model with 539,820 B cells (including B naive, B intermediate, and
B memory cells) from TenK10K phase 1 single-cell RNA sequencing data. The training used
expression features of 2,351 highly variable genes selected with Scanpy function
highly_variable_genes (min_mean=0.0123, max_mean=3, min_disp=0.5) with human Biological
Process Gene Ontology (GOBP) database as a guide, filtered to the top 400 most informative
GOBP pathways based on the presence of pathway genes in the highly variable gene list. We then
extracted the attention-based latent space for UMAP representation, and extracted the cell function
scores followed by transformation of each cell function score to approximate a normal distribution
with a zero mean and one unit variance.
704

As a proof-of-concept to explore the function of cells that are enriched for specific phenotypes, we
intersected scDeepID cell function score with scDRS score for systemic lupus erythematosus
(scDRS$_{SLE}$) amongst 30,000 subsampled B cells used in the scDRS analysis. We first grouped
these cells into SLE-enriched cells (cell-level $P_{scDRS-SLE}$) and non-SLE-enriched cells, and
compared mean cell function scores between the two groups using a one-sided *T*-test for each
pathway under analysis followed by FDR correction.
711

Estimating the support of single-cell genetics for drug target validation
To evaluate the utility of single-cell genetics for drug target identification, we cross-referenced our
cell-type resolved MR results with a target-evidence association score and drug development
activity dataset sourced from Open Targets Platform (OTP) [24] version 25.06. Analysis were limited
to a set of 12,873 protein-coding genes tested in the MR analysis and 57 diseases with at least one
matching indication available in the Open Targets Platform database, resulting in a total of 733,761
possible pairs of target (gene) and indication (disease) – the target-indication universe in this study.
We used Ensembl gene ID to match tested genes to OTP targets, and used Experimental Factor
Ontology (EFO) ID to match tested phenotypes to OTP indications.

First, we extracted drug development activity data in OTP (sourced from ChEMBL[25]) and
calculated the maximum evidence score in OTP for every target-indication pair. Following
ChEMBL classification, we categorised the evidence score into the following:
724

Maximum Clinical Development Stage	Evidence Score
Phase I	0.1
Phase II	0.2
Phase III	0.7
Phase I+	0.1 or more
Phase II+	0.2 or more
Phase III+	0.7 or more
Approved	1

725
For every category, we computed the 2x2 intersection between target-indication inside or outside
the category and target-indication with or without MR support, resulting in four possible
combinations: in the category & with MR support, in the category & without MR support, outside
the category & with MR support, and outside the category & without MR support. Using this 2x2
contingency table, we then computed the odds ratio for being in the category, comparing between
target-indication pairs with and without MR support. P-value and 95% lower confidence interval
were calculated using a one-sided Fisher's exact test implemented in *fisher.test()* R function. For
this analysis, MR support was defined as a significant MR association ($Q_{MR} < 0.05$ and $P_{HEIDI} \geq$
0.01) in at least one cell type under analysis.
735
Second, for every matched target-indication pair under analysis, we extracted the overall OTP
evidence score which quantifies aggregated evidence from data sources of genetic association,
somatic mutation, known drug, affected pathway, literature, RNA expression, and animal model.
We took the maximum of direct (evidence referring directly to indication ID) and indirect
association score (evidence referring to indication ID or any of its descendant IDs in EFO). The
association score takes a value between 0 and 1, where a higher score indicates more evidence
supporting the target-indication association relative to a theoretical maximum. We computed the
mean score of target-indication with and without MR support, and tested the difference using a
two-sample Welch's T-test implemented in *t.test()* R function. We then extracted the evidence
score stratified by data score, computed the genetic evidence score (unweighted mean of scores
from genetic association sources) and non-genetic evidence (unweighted mean of scores from non-
genetic association sources), and repeated the test procedures for the two evidence sources.

Third, we assessed the concordance between MR-predicted effect direction and drug mechanism
across clinical development phases. The MR-predicted effect direction for a target-indication pair
was derived by taking the majority of effect directions across cell types with significant MR
associations. To remove ambiguity, target-indication with equal number of positive and negative
effects across cell types were excluded from the analysis. The drug mechanism effects were
extracted from ChEMBL drug data in OTP, and matched with ChEMBL ID of drug with maximum
clinical development phase for a given target-indication pair.
755
Crohn's disease case study
We extracted all MR associations for Crohn's disease which passed the discovery threshold
of FDR-adjusted $Q < 5\%$ and $P_{HEIDI} > 0.01$.. For each unique MR gene identified, we constructed
a Boolean annotation (TRUE / FALSE) based on membership in: 1) the canonical gene list, 2) the
drug target gene list 3) the drug target pathways, 4) cell type-specific MR association (whether the
MR association is only identified in one cell type), 5) discordance of MR effect direction in at least
two cell types, and 6) differentially expressed in Crohn's disease colon tissue where the major cell
types are matched (**Supplementary Table 13**).
764
Canonical genes from Crohn's disease were downloaded from a systematic review of genes
associated with Crohn's disease[99] The full list (n = 1,172) was filtered to belong to Categories
"Experimental evidence of variant", "Other evidences of genetic alterations", "Treatment
Response" , "Biologically related but no evidence of mutation", with a Document Score >= 8 and
Abstract Number >= 10, resulting in a list of 49 genes (**Supplementary Table 15**). The drug target
genes were extracted from review papers[100,101], and the drug pathway genes (IL23/12, ITGA4,
JAK/STAT, TNF) were extracted from GSEA platform[102,103] following the approach described
previously[70] (**Supplementary Table 16**). The list of differentially expressed genes was derived
from an external dataset of single-cell RNA sequencing in intestinal tissues from 46 Crohn's
disease patients and 25 healthy controls, comparing both inflamed and non-inflamed disease tissue
with healthy tissue.[33] To derive this annotation, we extracted differentially expressed genes in the
colon (pre-computed Discrete FDR < 0.05) across immune cell types. We harmonised the original
cell type annotation with the TenK10K cell type annotation used in this study by matching major
cell types (**Supplementary Table 17**). We then identified MR and DEG genes in matched major
cell types, and checked for concordance of direction of effect by comparing the beta sign between
MR and the Discrete model of DEG (**Supplementary Table 14**). This generated multiple
combinations of gene-major cell type pairs, based on unique combinations of original MR cell
types and DEG cell types. 'All concordant' corresponds to cases where every gene-MR cell type-
DEG cell type set has a matched direction of effect between MR and DEG. 'All discordant'
corresponds to cases where every gene-MR cell type-DEG cell type set has an unmatched direction
of effect between MR and DEG. 'Mixed concordance' corresponds to genes which have discordant
directions between or within major cell types.

To evaluate expression of the genes of interest in colon tissue (**Figure 5d**), we extracted sc-
RNAseq data from colon tissue of Crohn's disease patients[33], downloaded from CELLxGENE[104].
We present the gene expression as normalised counts on the original Uniform Manifold
Approximation and Projection (UMAP) embedding using Scanpy, stratified by 'Type' into
"Healthy", "Non-inflamed Crohn's disease", and "Inflamed Crohn's disease" and filtered to
immune cell types with matched major cell types annotation in the TenK10K. The original cell
annotation and distribution of cells before and after filtering is presented in **Supplementary**
Figure 15.
795

Author contribution
A.H., A.S., R.T., and J.E.P. designed the overall study. A.H., A.S., R.T., B.B., and J.E.P.
contributed to the initial writing of the manuscript. A.H. and A.S. performed single-cell MR
analysis. A.H. designed and performed MAGMA, scDRS, and drug target support analyses. R.T.
designed and performed the proof-of-concept analysis in Crohn's disease. B.B. and A.S.E.C.
performed the sc-eQTL mapping in the TenK10K led by J.E.P., with genotype data processing led
by K.M.dL. and D.G.M. A.S., H.A.T., and A.H. processed GWAS summary statistics. E.S. and
E.S.Z. contributed to the sample collection, processing, and generation of single-cell RNA
sequencing data. A.X, J.F., and P.C.A. provided input for single-cell MR and scDRS analysis.
H.L.H. designed and performed the cell function analysis with scDeepID. A.H., A.S., B.B., R.T.,
and H.L.H. contributed to the design and generation of figures, tables, and the computational
pipeline for analysis. G.A.F. led the BioHEART study and A.W.H. led the Tasmanian Ophthalmic
Biobank study, of which samples were included in the sc-eQTL mapping. J.E.P. contributed to
funding acquisition and supervision for the study. All authors reviewed and approved the final
version of the manuscript.
811

Competing interests
813
D.G.M. is a paid advisor to Insitro and GSK, and receives research funding from Google and
814
Microsoft, unrelated to the work described in this manuscript. G.A.F reports grants from National
815
Health and Medical Research Council (Australia), Abbott Diagnostic, Sanofi, Janssen
816
Pharmaceuticals, and NSW Health, and honorarium from CSL, CPC Clinical Research, Sanofi,
817
Boehringer-Ingelheim, Heart Foundation, and Abbott. G.A.F serves as Board Director for the
818
Australian Cardiovascular Alliance (past President), Executive Committee Member for CPC
819
Clinical Research, Founding Director and CMO for Prokardia and Kardiomics, and Executive
820
Committee member for the CAD Frontiers A2D2 Consortium. In addition, G.A.F serves as CMO
821
for the non-profit, CAD Frontiers, with industry partners including, Novartis, Amgen, Siemens
822
Healthineers, ELUCID, Foresite Labs LLC, HeartFlow, Canon, Cleerly, Caristo, Genentech,
823
Artyra, and Bitterroot Bio, Novo Nordisk and Allelica. G.A.F also reports the following patents:
824
"Patent Biomarkers and Oxidative Stress" awarded USA May 2017 (US9638699B2) issued to
825
Northern Sydney Local Health District, "Use of P2X7R antagonists in cardiovascular disease"
826
PCT/AU2018/050905 licensed to Prokardia, "Methods for treatment and prevention of vascular
827
disease" PCT/AU2015/000548 issued to The University of Sydney/Northern Sydney Local Health
828
District, "Methods for predicting coronary artery disease" AU202290266 issued to The University
829
of Sydney, and the patent "Novel P2X7 Receptor Antagonists" PCT/AU2022/051400
830
(23.11.2022), International App No: WO/2023/092175 (01.06.2023), issued to The University of
831
Sydney.
832

833
Data availability
834
The main single-cell MR association results will be made publicly available via Zenodo website
835
prior to acceptance.
836

837
Code availability
838
Analysis code will be made publicly available at https://github.com/powellgenomicslab/tenk10k-
839
causal-paper
840

References

1. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating the dark road from association to function. *Am. J. Hum. Genet.* **93**, 779–797 (2013).
2. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits: From polygenic to omnigenic. *Cell* **169**, 1177–1186 (2017).
3. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. *Science* **376**, eabf3041 (2022).
4. Nathan, A. *et al.* Single-cell eQTL models reveal dynamic T cell state dependence of disease loci. *Nature* **606**, 120–128 (2022).
5. Cuomo, A. S. E., Nathan, A., Raychaudhuri, S., MacArthur, D. G. & Powell, J. E. Single-cell genomics meets human genetics. *Nat. Rev. Genet.* (2023) doi:10.1038/s41576-023-00599-5.
6. Elmentaite, R. *et al.* Cells of the human intestinal tract mapped across space and time. *Nature* **597**, 250–255 (2021).
7. Perez, R. K. *et al.* Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. *Science* **376**, eabf1970 (2022).
8. Bryois, J. *et al.* Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. *Nat. Neurosci.* **25**, 1104–1112 (2022).
9. Natri, H. M. *et al.* Cell-type-specific and disease-associated expression quantitative trait loci in the human lung. *Nat. Genet.* **56**, 595–604 (2024).
10. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-seq data. *Nat. Genet.* **54**, 1572–1580 (2022).
11. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. *Nat. Genet.* **54**, 1479–1492 (2022).
12. Porcu, E. *et al.* Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants of complex and clinical traits. *Nat. Commun.* **10**, 3300 (2019).
13. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nature Genetics* **48**, 481–487 (2016).
14. Wu, Y. *et al.* Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nat. Commun.* **9**, 918 (2018).
15. Cuomo, A. S. E. *et al.* Impact of Rare and Common Genetic Variation on Cell Type-Specific Gene Expression. *Genetic and Genomic Medicine* (2025).
16. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
17. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310 (2021).
18. Middel, P., Raddatz, D., Gunawan, B., Haller, F. & Radzun, H.-J. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. *Gut* **55**, 220–227 (2006).
19. Collin, M. & Bigley, V. Human dendritic cell subsets: an update. *Immunology* **154**, 3–20 (2018).
20. Swiecki, M. & Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. *Nat. Rev. Immunol.* **15**, 471–485 (2015).
21. Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic

evidence on clinical success. *Nature* **629**, 624–629 (2024).

22.   Nelson, M. R. *et al.* The support of human genetic evidence for approved drug
indications. *Nature Genetics* **47**, 856–860 (2015).

23.   Dann, E. *et al.* Estimating the impact of single-cell RNA sequencing of human tissues on
drug target validation. *medRxiv* 2024.04.04.24305313 (2024) doi:10.1101/2024.04.04.24305313.

24.   Buniello, A. *et al.* Open Targets Platform: facilitating therapeutic hypotheses building in
drug discovery. *Nucleic Acids Res* **53**, D1467–D1475 (2025).

25.   Zdrazil, B. *et al.* The ChEMBL Database in 2023: a drug discovery platform spanning
multiple bioactivity data types and time periods. *Nucleic Acids Res.* **52**, D1180–D1192 (2024).

26.   Hampel, H. *et al.* The amyloid-β pathway in Alzheimer's disease. *Mol. Psychiatry* **26**,
5481–5503 (2021).

27.   Zheng, Z. *et al.* Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.
Signal Transduct. Target. Ther. **9**, 234 (2024).

28.   Lincoff, A. M. *et al.* Semaglutide and cardiovascular outcomes in obesity without
diabetes. *N. Engl. J. Med.* **389**, 2221–2232 (2023).

29.   Ryan, D. H. *et al.* Long-term weight loss effects of semaglutide in obesity without
diabetes in the SELECT trial. *Nat. Med.* **30**, 2049–2057 (2024).

30.   Roda, G. *et al.* Crohn's disease. *Nat. Rev. Dis. Primers* **6**, 22 (2020).

31.   Torres, J., Mehandru, S., Colombel, J.-F. & Peyrin-Biroulet, L. Crohn's disease. *Lancet*
389, 1741–1755 (2017).

32.   de Lange, K. M. & Barrett, J. C. Understanding inflammatory bowel disease via
immunogenetics. *J. Autoimmun.* **64**, 91–100 (2015).

33.   Kong, L. *et al.* The landscape of immune dysregulation in Crohn's disease revealed
through single-cell transcriptomic profiling in the ileum and colon. *Immunity* **56**, 444–458.e5
(2023).

34.   Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J. & Richards, J. B.
Genetic architecture: the shape of the genetic contribution to human traits and disease. *Nat. Rev.*
Genet. **19**, 110–124 (2018).

35.   Wray, N. R., Wijmenga, C., Sullivan, P. F., Yang, J. & Visscher, P. M. Common disease
is more complex than implied by the core gene omnigenic model. *Cell* **173**, 1573–1580 (2018).

36.   Mackay, T. F. C. & Anholt, R. R. H. Pleiotropy, epistasis and the genetic architecture of
quantitative traits. *Nat. Rev. Genet.* **25**, 639–657 (2024).

37.   Stankey, C. T. *et al.* A disease-associated gene desert directs macrophage inflammation
through ETS2. *Nature* **630**, 447–456 (2024).

38.   Jackson, S. W. *et al.* B cell IFN-γ receptor signaling promotes autoimmune germinal
centers via cell-intrinsic induction of BCL-6. *J. Exp. Med.* **213**, 733–750 (2016).

39.   Burdett, T. *et al.* GWAS Catalog. https://www.ebi.ac.uk/gwas/genes/ZBTB38.

40.   Ocskó, T. *et al.* Transcription factor Zbtb38 downregulates the expression of anti-
inflammatory IL1r2 in mouse model of rheumatoid arthritis. *Biochim. Biophys. Acta Gene Regul.*
Mech. **1861**, 1040–1047 (2018).

41.   Yan, M. *et al.* Dynamic regulatory networks of T cell trajectory dissect transcriptional
control of T cell state transition. *Mol. Ther. Nucleic Acids* **26**, 1115–1129 (2021).

42.   He, C. *et al.* NCF4 dependent intracellular reactive oxygen species regulate plasma cell
formation. *Redox Biol.* **56**, 102422 (2022).

43.   Buil, A. *et al.* Gene-gene and gene-environment interactions detected by transcriptome
sequence analysis in twins. *Nat. Genet.* **47**, 88–91 (2015).

44.   Garrido-Martín, D., Borsari, B., Calvo, M., Reverter, F. & Guigó, R. Identification and
analysis of splicing quantitative trait loci across multiple tissues in the human genome. *Nat.*
Commun. **12**, 727 (2021).
45.   Yamaguchi, K. *et al.* Splicing QTL analysis focusing on coding sequences reveals
mechanisms for disease susceptibility loci. *Nat. Commun.* **13**, 4659 (2022).
46.   Munafò, M. R., Higgins, J. P. T. & Smith, G. D. Triangulating evidence through the
inclusion of genetically informed designs. *Cold Spring Harb. Perspect. Med.* **11**, a040659
(2021).
47.   Luo, J. *et al.* Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab.
J. Mol. Biol. **402**, 797–812 (2010).
48.   Ma, C., Panaccione, R., Khanna, R., Feagan, B. G. & Jairath, V. IL12/23 or selective
IL23 inhibition for the management of moderate-to-severe Crohn's disease? *Best Pract. Res.*
Clin. Gastroenterol. **38-39**, 101604 (2019).
49.   Verstockt, B. *et al.* IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Nat. Rev. Gastroenterol. Hepatol. **20**, 433–446 (2023).
50.   Alquicira-Hernandez, J., Sathe, A., Ji, H. P., Nguyen, Q. & Powell, J. E. scPred: accurate
supervised method for cell-type classification from single-cell RNA-seq data. *Genome Biol.* **20**,
264 (2019).
51.   Michielsen, L., Reinders, M. J. T. & Mahfouz, A. Hierarchical progressive learning of
cell identities in single-cell data. *Nat. Commun.* **12**, 2799 (2021).
52.   Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–
3587.e29 (2021).
53.   Zhou, W. *et al.* Efficient and accurate mixed model association tool for single-cell eQTL
analysis. *Genetic and Genomic Medicine* (2024).
54.   Vuckovic, D. *et al.* The polygenic and monogenic basis of blood traits and diseases. *Cell*
182, 1214–1231.e11 (2020).
55.   Chai, R. C. *et al.* Multiscale analysis and functional validation of the cellular and genetic
determinants of skeletal disease. *Genetics* (2024).
56.   Rashkin, S. R. *et al.* Pan-cancer study detects genetic risk variants and shared genetic
basis in two large cohorts. *Nat. Commun.* **11**, 4423 (2020).
57.   Fernandez-Rozadilla, C. *et al.* Deciphering colorectal cancer genetics through multi-omic
analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. *Nat.*
Genet. **55**, 89–99 (2023).
58.   McKay, J. D. *et al.* Large-scale association analysis identifies new lung cancer
susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat.*
Genet. **49**, 1126–1132 (2017).
59.   Adolphe, C. *et al.* Genetic and functional interaction network analysis reveals global
enrichment of regulatory T cell genes influencing basal cell carcinoma susceptibility. *Genome*
Med. **13**, 19 (2021).
60.   Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
population. *Nature* **613**, 508–518 (2023).
61.   Verma, A. *et al.* Diversity and scale: Genetic architecture of 2068 traits in the VA Million
Veteran Program. *Science* **385**, eadj1182 (2024).
62.   Zhang, H. *et al.* Genome-wide association study identifies 32 novel breast cancer
susceptibility loci from overall and subtype-specific analyses. *Nat. Genet.* **52**, 572–581 (2020).
63.   Wang, A. *et al.* Characterizing prostate cancer risk through multi-ancestry genome-wide

discovery of 187 novel risk variants. *Nat. Genet.* **55**, 2065–2074 (2023).

64.   Kar, S. P. *et al.* Genome-wide analyses of 200,453 individuals yield new insights into the
causes and consequences of clonal hematopoiesis. *Nat. Genet.* **54**, 1155–1166 (2022).

65.   Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human
phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).

66.   Chiou, J. *et al.* Interpreting type 1 diabetes risk with genetics and single-cell
epigenomics. *Nature* **594**, 398–402 (2021).

67.   Bentham, J. *et al.* Genetic association analyses implicate aberrant regulation of innate and
adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat. Genet.* **47**,
1457–1464 (2015).

68.   Ishigaki, K. *et al.* Multi-ancestry genome-wide association analyses identify novel
genetic mechanisms in rheumatoid arthritis. *Nat. Genet.* **54**, 1640–1651 (2022).

69.   Stuart, P. E. *et al.* Transethnic analysis of psoriasis susceptibility in South Asians and
Europeans enhances fine-mapping in the MHC and genomewide. *HGG Adv.* **3**, 100069 (2022).

70.   de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of
multiple integrin genes in inflammatory bowel disease. *Nat. Genet.* **49**, 256–261 (2017).

71.   International Multiple Sclerosis Genetics Consortium (IMSGC) *et al.* Analysis of
immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat. Genet.*
45, 1353–1360 (2013).

72.   Budu-Aggrey, A. *et al.* European and multi-ancestry genome-wide association meta-
analysis of atopic dermatitis highlights importance of systemic immune regulation. *Nat.*
Commun. **14**, 6172 (2023).

73.   COVID-19 Host Genetics Initiative. A second update on mapping the human genetic
architecture of COVID-19. *Nature* **621**, E7–E26 (2023).

74.   Lammi, V. *et al.* Genome-wide association study of long COVID. *Nat. Genet.* **57**, 1402–
1417 (2025).

75.   Bian, S. *et al.* Genetic determinants of IgG antibody response to COVID-19 vaccination.
Am. J. Hum. Genet. **111**, 181–199 (2024).

76.   Suzuki, K. *et al.* Multi-ancestry genome-wide study in >2.5 million individuals reveals
heterogeneity in mechanistic pathways of type 2 diabetes and complications. *medRxiv* (2023)
doi:10.1101/2023.03.31.23287839.

77.   Zhao, C., Ma, T., Cheng, X., Zhang, G. & Bai, Y. Genome-wide association study of
cardiometabolic multimorbidity in the UK Biobank. *Clin. Genet.* **106**, 72–81 (2024).

78.   Adlam, D. *et al.* Genome-wide association meta-analysis of spontaneous coronary artery
dissection identifies risk variants and genes related to artery integrity and tissue-mediated
coagulation. *Nat. Genet.* **55**, 964–972 (2023).

79.   Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes
for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815 (2022).

80.   Zheng, S. L. *et al.* Genome-wide association analysis provides insights into the molecular
etiology of dilated cardiomyopathy. *Nat. Genet.* **56**, 2646–2658 (2024).

81.   Henry, A. *et al.* Genome-wide association study meta-analysis provides insights into the
etiology of heart failure and its subtypes. *Nat. Genet.* **57**, 815–828 (2025).

82.   Surakka, I. *et al.* Multi-ancestry meta-analysis identifies 2 novel loci associated with
ischemic stroke and reveals heterogeneity of effects between sexes and ancestries. *bioRxiv*
(2022) doi:10.1101/2022.02.28.22271647.

83.   Kim, J. J. *et al.* Multi-ancestry genome-wide association meta-analysis of Parkinson's

disease. *Nat. Genet.* **56**, 27–36 (2024).

84.   Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and
related dementias. *Nat. Genet.* **54**, 412–436 (2022).

85.   Hautakangas, H. *et al.* Genome-wide analysis of 102,084 migraine cases identifies 123
risk loci and subtype-specific risk alleles. *Nat. Genet.* **54**, 152–160 (2022).

86.   Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the
genetic architecture and implicate several cognitive domains. *Nat. Genet.* **55**, 198–208 (2023).

87.   Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum
disorder. *Nat. Genet.* **51**, 431–444 (2019).

88.   Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
schizophrenia. *Nature* **604**, 502–508 (2022).

89.   Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid
psychiatric disorders using genome-wide analyses. *Nat. Med.* **29**, 1832–1844 (2023).

90.   Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder
cases provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).

91.   Tsuo, K. *et al.* Multi-ancestry meta-analysis of asthma identifies novel associations and
highlights the value of increased power and diversity. *Cell Genom.* **2**, 100212 (2022).

92.   Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery
across human disease. *Cell Genom.* **2**, 100192 (2022).

93.   Allen, R. J. *et al.* Genome-wide association study of susceptibility to idiopathic
pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* **201**, 564–574 (2020).

94.   McDonald, M.-L. N. *et al.* Novel genetic loci associated with osteoarthritis in multi-
ancestry analyses in the Million Veteran Program and UK Biobank. *Nat. Genet.* **54**, 1816–1826
(2022).

95.   Day, F. *et al.* Large-scale genome-wide meta-analysis of polycystic ovary syndrome
suggests shared genetic architecture for different diagnosis criteria. *PLoS Genet.* **14**, e1007813
(2018).

96.   Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain
and inflammatory conditions. *Nat. Genet.* **55**, 423–436 (2023).

97.   Lo Faro, V. *et al.* Novel ancestry-specific primary open-angle glaucoma loci and shared
biology with vascular mechanisms and cell proliferation. *Cell Rep. Med.* **5**, 101430 (2024).

98.   John D. Storey with contributions from Andrew J. Bass, A. A. D. R. *Qvalue*.
(Bioconductor, 2017). doi:10.18129/B9.BIOC.QVALUE.

99.   Garza-Hernandez, D. *et al.* A systematic review and functional bioinformatics analysis of
genes associated with Crohn's disease identify more than 120 related genes. *BMC Genomics* **23**,
302 (2022).

100.   Feng, Z. *et al.* Breaking through the therapeutic ceiling of inflammatory bowel disease:
Dual-targeted therapies. *Biomed. Pharmacother.* **158**, 114174 (2023).

101.   Tyebally, R., Xue, A. & Powell, J. E. The potential clinical impact of cell type-specific
genetic regulation: Crohn's disease. *Clin. Transl. Med.* **13**, e1474 (2023).

102.   Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550
(2005).

103.   Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation
are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).

104.   CZI Single-Cell Biology Program *et al.* CZ CELL×GENE Discover: A single-cell data

platform for scalable exploration, analysis and modeling of aggregated data. *bioRxiv* (2023)
doi:10.1101/2023.10.30.563174.
1074

Supplementary Figures

Supplementary Figure 1. Summary of MR associations across 53 diseases and 28 immune cell types. The heatmap shows the number of MR-significant genes per cell type (rows) and traits (columns), binned into deciles with the first two deciles containing zero-only values merged into one. Left-side bar plots indicate (i) the $\log_{10}$-transformed number of single cells per cell type (left) and (ii) the number and proportion of eGenes with at least one MR-significant disease association (right). Top annotations display the number of MAGMA-significant GWAS genes per trait that are also eGenes (top), the total number of MR-significant genes per trait (middle), and the number of cell types in which each gene is MR-significant (bottom). All MR associations meet the threshold of $Q_{MR} < 0.05$ and $P_{HEIDI} \geq 0.01$.

Supplementary Figure 2. Summary of MR associations across 31 biomarker traits and 28 immune cell types. The heatmap shows the number of MR-significant genes per cell type (rows) and traits (columns), binned into deciles. Left-side bar plots indicate (i) the $\log_{10}$-transformed number of single cells per cell type (left) and (ii) the number and proportion of eGenes with at least one MR-significant disease association (right). Top annotations display the number of MAGMA-significant GWAS genes per trait that are also eGenes (top), the total number of MR-significant genes per trait (middle), and the number of cell types in which each gene is MR-significant (bottom). All MR associations meet the threshold of $Q_{MR} < 0.05$ and $P_{HEIDI} \geq 0.01$.

Supplementary Figure 3. Number of significant MR associations and number of MR tests across cell types

Supplementary Figure 4. Number of MR and GWAS genes across 100 complex traits.

Supplementary Figure 5. Overlaps between MR and GWAS genes across phenotypes. For a given trait, MR genes are defined as genes showing MR association ($Q_{MR} < 0.05$, $P_{HEIDI} \geq 0.01$) in at least one cell type and GWAS genes are defined as associated genes with Q_{MAGMA} <0.05. Bar charts denote numbers of unique MR genes (left panel) and proportion of MR genes (right panel), categorised into whether the gene is also identified as GWAS genes. Numbers of MR & GWAS genes / GWAS only genes are labelled on the left / right hand side of the proportion bar charts.

Supplementary Figure 6. Overlaps between genes identified in MR using single-cell eQTL instruments from TenK10K and using bulk-tissue eQTL instruments from eQTLgen across phenotypes. For a given trait, MR genes are defined as genes showing MR association ($Q_{MR} < 0.05$, $P_{HEIDI} \geq 0.01$), in at least one cell type for the TenK10K analysis. Bar charts denote numbers of unique MR genes (left panel) and proportion of MR genes (right panel) identified from the TenK10K analysis, categorised into whether the gene is also identified in the eQTLgen analysis. Numbers of TenK10K & eQTLgen MR

genes / TenK10K only MR genes are labelled on the left / right hand side of the proportion bar charts.

Supplementary Figure 7. Polygenic enrichment of phenotypes across immune cell types

Supplementary Figure 8. The mean scDeepID cell function scores of the top 50 cell functions, based on the FDR-adjusted one-side *T*-test between SLE-enriched (cell-level scDRS $P-$value for SLE polygenic enrichment < 0.05) and non$-$SLE$-$enriched cells (cell$-$level scDRS P$-$value $\geq$ 0.05). To pinpoint the most relevant cell functions, we only visualise cell functions with mean score > 0.2 in SLE-enriched cells.

Supplementary Figure 9. a) UMAP representation of the 30,000 sampled B cells used in scDRS analysis. The UMAP was generated from scDeepID attention embedding, with scores of 5 selected cell functions, as well as the cell type labels. **b)** Distribution of the top 5 cell functions scores from (A). **c)** Mean scores of the top 5 cell functions across deciles of scDRS SLE score.

Supplementary Figure 10. Distribution of single-cell disease relevance score (scDRS) for Crohn's disease across two sampling strategies: 1) left panel: per-cell-type proportional sampling of 10% of cells analysed in the TenK10K phase 1 study, and 2) right panel: maximum of 10,000 cells per cell type (as used in the main analysis presented in the manuscript).

Supplementary Figure 11. Proportion of cells showing polygenic enrichment for Crohn's disease (cell-level Monte-Carlo *P* value) < 0.05 derived from single-cell disease relevance score (scDRS) across two sampling strategies: 1) left panel: per-cell-type proportional sampling of 10% of cells analysed in the TenK10K phase 1 study, and 2) right panel: maximum of 10,000 cells per cell type (as used in the main analysis presented in the manuscript).

Supplementary Figure 12. Target-indication pairs in Open Targets Platform (version 25.06) with single-cell MR support.

Supplementary Figure 13. Summary of cell type-resolved MR results for Crohn's disease **a)** Number of genes showing putative causal associations with Crohn's disease ($Q_{MR} < 0.05$; $P_{HEIDI} \geq 0.01$) across cell types. **b)** Total number of tested genes across cell types.

Supplementary Figure 14. Comparison of TenK10K single-cell MR with GWAS and eQTLgen bulk MR for Crohn's disease. Number of significant MR genes grouped by the number of cell types they are significant in. This is compared with the number of genes that are also significant in a) MAGMA, a GWAS-only based gene prioritisation method and b) bulk whole blood eQTLgen eQTL MR using the same Crohn's GWAS summary statistics.

Supplementary Figure 15. Harmonised cell type annotation between MR and DEG. **a)** Left: The original annotation for the Crohn's colon immune cell dataset. Right: Harmonised annotation based on major cell types (**Supplementary Table 17**). **b)** Filtered version of (a) based on matched major cell types between MR and DEG. The cell types filtered out are macrophages, immune cycling cells, intraepithelial NK-like cells, and mast cells.

Supplementary Figure 16. Concordance of direction of effect in MR and DEG for genes with matched major cell type pairs. Each dot represents a gene-MR cell type-DEG cell type set, which belongs to a single matched major cell type between studies. *TNFRSF18* is highlighted as an example, labelled by 'MR cell type | DEG cell type', under the CD4 T major cell type group. 'All concordant' corresponds to cases where every gene-MR cell type-DEG cell type set has a matched direction of effect between MR and DEG. 'All discordant' corresponds to cases where every gene-MR cell type-DEG cell type set has an unmatched direction of effect between MR and DEG. 'Mixed concordance' corresponds to genes which have discordant directions between or within major cell types (see **Methods**, **Supplementary Table 14**).